CJC 1295(No DAC) + Ipamorelin

The CJC-1295 (No DAC) + Ipamorelin blend combines two synthetic peptides that are widely studied for their complementary roles in endocrine and growth hormone signaling pathways. CJC-1295 (No DAC) is a modified Growth Hormone-Releasing Hormone (GHRH) analog designed without a Drug Affinity Complex (DAC), making it well-suited for research examining shorter-acting pulsatile signaling rather than prolonged exposure. Ipamorelin is a highly selective growth hormone secretagogue that has been studied for its ability to stimulate pituitary signaling while exhibiting minimal activity at other receptor systems.

When used together in laboratory research, these peptides provide a valuable platform for investigating coordinated endocrine signaling, neuroendocrine communication, and downstream metabolic pathways. Their complementary mechanisms make this blend particularly useful for studies evaluating pulsatile hormone release, receptor interactions, and systemic signaling dynamics.

Research Benefits

• Combines two extensively studied research peptides into a single formulation.
• Features CJC-1295 (No DAC) for research focused on shorter-duration, pulsatile endocrine signaling.
• Includes Ipamorelin, a selective secretagogue commonly studied for targeted pituitary pathway activation.
• Supports investigation of growth hormone signaling and neuroendocrine communication pathways.
• Enables evaluation of potential synergistic interactions between GHRH analog and secretagogue signaling.
• Manufactured using high-purity, research-grade materials for laboratory applications.

For Research Use Only. This product is intended exclusively for laboratory and scientific research. It is not intended for human or veterinary use, diagnosis, treatment, or consumption.